Target | CD25 |
---|
Application | FC, IF, IHC |
---|
Clonality | Monoclonal |
---|
Conjugate | Allophycocyanin (APC) |
---|
Isotype | Human IgG1κ |
---|
Immunogen | Human CD25 |
---|
Species Reactivity | Human, Cynomolgus Monkey, Rhesus Monkey |
---|
Formulation | This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. |
---|
Research Area | Cancer, Immunology |
---|
Description/Background | CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2Rα. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25. Anti-Human IL-2R alpha (CD25) (Basiliximab) utilizes the same variable regions from the therapeutic antibody Basiliximab making it ideal for research projects. |
---|
Storage Temperature | This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze. |
---|
Protocols | FC, IF, IHC |
---|
Clone Number | Hu107 |
---|
Concentration | 0.2 mg/ml |
---|
Regulatory Statement | For Research Use Only. Not for use in diagnostic procedures. |
---|